Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2017-12-29

Clinical Trial Update: Study of Anlotinib in Patients With Gastric Cancer(ALTER0503) [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial update for Anlotinib in gastric cancer (ALTER0503) spanning Phase 2 and Phase 3.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Anlotinib (anlotinib)

Snippet

Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Conditions: Gastric Cancer | Phase 2, Phase 3 | Status: UNKNOWN